entertainment -WSS

entertainment

author：explore 2025-08-12 11:28:53 - browse：1938

hazy pages of aetna.com layered next to each other, as shown through a kaleidoscopic glass — Adobe

CVS Health is preparing to make significant changes to its 2025 Medicare Advantage plans, which could potentially drive away 10% of its membership, the company’s chief financial officer said at an investment banking conference Tuesday.

“The goal for next year is margin over membership,” CVS CFO Tom Cowhey said at the conference, hosted by Bank of America. “Could we lose up to 10% of our existing Medicare members next year? That’s entirely possible. And that’s OK, because we need to get this business back on track.”

CVS, through its Aetna subsidiary, is the third-largest Medicare Advantage insurer, with more than 4.2 million enrollees as of April, according to the latest federal data. That means next year CVS could push out up to 420,000 older adults and people with disabilities on its Medicare Advantage plans, forcing them to choose another plan.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

WSS

ADCs take center stage as promising cancer treatments

Roche drug slashes death risk in early

For AI in health care standards, federal regulators join with industry group

Questions loom on AstraZeneca cancer drug as safety concerns ebb

State of the Union pitch: Bigger Medicare drug price negotiations

STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

entertainment

How to save PrEP access — and even expand it

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA clears Verve to begin U.S. study of gene

Tori Bowie and the unacceptable rates of Black maternal death

ADCs take center stage as promising cancer treatments

How to save PrEP access — and even expand it

Change Healthcare: What is it, why does its cyberattack matter?

Medicare details structure of new drug price negotiation program

Longer MASH drug regimen improved liver, Akero study finds

focus

STAT Summit: The economic case for universal basic health care

Fetal cell organoids grown from amniotic fluid, study finds

Stem cell biologist probes earliest stages of human development

FDA clears Verve to begin U.S. study of gene

State of the Union pitch: Bigger Medicare drug price negotiations

Ozempic has benefits for kidney disease as well as diabetes

Wikipedia

hotspot

hotspot

hotspot